Based in San Carlos, California, USA, with operations also in Massachusetts and Texas, LakePharma specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates. The company has six facilities and employs 235 people.

According to Curia, LakePharma has contributed to the development of more than 200 therapeutic or diagnostic products, serving 22 of the top 25 global biopharma companies.

Once the transaction closes in the third quarter of 2021, the combined company will provide deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production.

“LakePharma will expand our integrated approach to provide biotech and pharmaceutical companies with small and large molecule research, development and manufacturing solutions,” said Curia chairman & CEO John Ratliff. “Funding and innovation in the biotech sector remains strong. Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharma’s multi-modality innovation and speed along with fill-finish solutions from Curia.”

Last month, Curia announced its purchase of Integrity Bio, a privately held biologics formulation and fill & finish company headquartered in Camarillo, California. The deal gives Curia a presence on the US West Coast, complementing its presence on the US East Coast, as well as in Europe and Asia.

Author: Elaine Burridge, Freelance Journalist